Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
General Infectious Disease
•
Gram Negative Resistance
•
Antimicrobial Resistance
Are you less likely to use cefiderocol for carbapenem-resistant Gram-negative bloodstream infections based on the GAME CHANGER trial showing non-inferiority to standard-of-care antibiotics?
Paterson DL, et al., PMID 41067237
Related Questions
What is your approach to antibiotic prophylaxis for spontaneous bacterial peritonitis in patients with cirrhosis?
What is your preferred empiric antibiotic escalation for a patient with chorioamnionitis with worsening signs of sepsis on single agent cefoxitin?
Do you routinely prescribe linezolid to patients who are concomitantly on methadone?
Do you recommend treatment of male partners for patients with recurrent bacterial vaginosis?
Do you avoid Daptomycin use when there is evidence of septic pulmonary emboli?
How have the results of the BALANCE trial, which demonstrated the noninferiority of 7 days of antibiotics compared to 14 days for non-S. aureus bloodstream infections, influenced your practice?
What factors do you consider when deciding between monotherapy with an antipseudomonal cephalosporin and combination therapy in ICU patients with Pseudomonas aeruginosa bloodstream infection who are not in septic shock?
What are your vaccine recommendations while patients are on biologics?
Do you recommend low or intermediate dosing of TMP-SMX over high dosing for the initial treatment of non-disseminated pulmonary nocardiosis?
How long would you hold antibiotics before performing a vertebral biopsy to optimize culture yield in a patient who has been on empiric antibiotics for a week for suspected vertebral osteomyelitis?
